Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 39 results.
User Information
Export Records
  1. 1.   Metabolic Syndrome, Physical Activity, and Inflammation: A Cross-Sectional Analysis of 110 Circulating Biomarkers in Japanese Adults
  2. Van Alsten, Sarah C.; Rabkin, Charles S.; Sawada, Norie; Shimazu, Taichi; Charvat, Hadrien; Yamaji, Taiki; Inoue, Manami; Kemp,Troy; Pinto,Ligia; Camargo, M. Constanza; Tsugane, Shoichiro; Song, Minkyo
  3. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2020, AUG; 29(8): 1639-1646.
  1. 2.   Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease
  2. Ramaswami, Ramya; Lurain, Kathryn; Peer, Cody J.; Serquina, Anna; Wang, Victoria; Widell, Anaida; Goncalves, Priscila; Steinberg, Seth M.; Marshall,Vickie; George, Jomy; Figg, William D.; Whitby,Denise; Ziegelbauer, Joseph; Uldrick, Thomas S.; Yarchoan, Robert
  3. BLOOD. 2020, JUN 18; 135(25): 2316-2319.
  1. 3.   Mesoderm-specific Stat3 deletion affects expression of Sox9 yielding Sox9-dependent phenotypes
  2. Hall, Michael; Murray, Caroline A.; Valdez, Michael J.; Perantoni, Alan
  3. PLOS GENETICS. 2017, Feb 6; 13(2): e1006610.
  1. 4.   Intra-individual variability over time in serum cytokine levels among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
  2. Hofmann, J. N.; Yu, K.; Bagni, R. K.; Lan, Q.; Rothman, N.; Purdue, M. P.
  3. Cytokine. 2011, Nov; 56(2): 145-148.
  1. 5.   High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy
  2. Uldrick, T. S.; Polizzotto, M. N.; Aleman, K.; O'Mahony, D.; Wyvill, K. M.; Wang, V.; Marshall, V.; Pittaluga, S.; Steinberg, S. M.; Tosato, G.; Whitby, D.; Little, R. F.; Yarchoan, R.
  3. Blood. 2011, Jun; 117(26): 6977-6986.
  1. 6.   An Interleukin-6-Related Systemic Inflammatory Syndrome in Patients Co-Infected with Kaposi Sarcoma-Associated Herpesvirus and HIV but without Multicentric Castleman Disease
  2. Uldrick, T. S.; Wang, V.; O'Mahony, D.; Aleman, K.; Wyvill, K. M.; Marshall, V.; Steinberg, S. M.; Pittaluga, S.; Maric, I.; Whitby, D.; Tosato, G.; Little, R. F.; Yarchoan, R.
  3. Clinical Infectious Diseases. 2010, Aug; 51(3): 350-358.
  1. 7.   PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3)
  2. Dossus, L.; Kaaks, R.; Canzian, F.; Albanes, D.; Berndt, S. I.; Boeing, H.; Buring, J.; Chanock, S. J.; Clavel-Chapelon, F.; Feigelson, H. S.; Gaziano, J. M.; Giovannucci, E.; Gonzalez, C.; Haiman, C. A.; Hallmans, G.; Hankinson, S. E.; Hayes, R. B.; Henderson, B. E.; Hoover, R. N.; Hunter, D. J.; Khaw, K. T.; Kolonel, L. N.; Kraft, P.; Ma, J.; Le Marchand, L.; Lund, E.; Peeters, P. H. M.; Stampfer, M.; Stram, D. O.; Thomas, G.; Thun, M. J.; Tjonnel, A.; Trichopoulos, D.; Tumino, R.; Riboli, E.; Virtamo, J.; Weinstein, S. J.; Yeager, M.; Ziegler, R. G.; Cox, D. G.
  3. Carcinogenesis. 2010, Mar; 31(3): 455-461.
  1. 8.   Inflammation-Associated Serum and Colon Markers as Indicators of Dietary Attenuation of Colon Carcinogenesis in ob/ob Mice
  2. Mentor-Marcel, R. A.; Bobe, G.; Barrett, K. G.; Young, M. R.; Albert, P. S.; Bennink, M. R.; Lanza, E.; Colburn, N. H.
  3. Cancer Prevention Research. 2009 2(1): 60-69.
  1. 9.   Effects of Manganese Superoxide Dismutase Silencing on Androgen Receptor Function and Gene Regulation: Implications for Castration-Resistant Prostate Cancer
  2. Sharifi, N.; Hurt, E. M.; Thomas, S. B.; Farrar, W. L.
  3. Clinical Cancer Research. 2008 14(19): 6073-6080.
  1. 10.   JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells
  2. Kiziltepe, T.; Hideshima, T.; Ishitsuka, K.; Ocio, E. M.; Raje, N.; Catley, L.; Li, C. Q.; Trudel, L. J.; Yasui, H.; Vallet, S.; Kutok, J. L.; Chauhan, D.; Mitsiades, C. S.; Saavedra, J. E.; Wogan, G. N.; Keefers, L. K.; Shami, P. J.; Anderson, K. C.
  3. Blood. 2007, Jul; 110(2): 709-718.
  1. 11.   Decreased brain damage and curtailed inflammation in transcription factor CCAAT/enhancer binding protein beta knockout mice following transient focal cerebral ischemia
  2. Kapadia, R.; Tureyen, K.; Bowen, K. K.; Kalluri, H.; Johnson, P. F.; Vemuganti, R.
  3. Journal of Neurochemistry. 2006, Sep; 98(6): 1718-1731.
  1. 12.   IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort
  2. Liu, Y. M.; Berthier-Schaad, Y.; Fallin, M. D.; Fink, N. E.; Tracy, R. P.; Klag, M. J.; Smith, M. W.; Coresh, J.
  3. Journal of the American Society of Nephrology. 2006, Mar; 17(3): 863-870.
  1. 13.   Molecular alterations in primary prostate cancer after androgen ablation therapy
  2. Best, C. J. M.; Gillespie, J. W.; Yi, Y. J.; Chandramouli, G. V. R.; Perlmutter, M. A.; Gathright, Y.; Erickson, H. S.; Georgevich, L.; Tangrea, M. A.; Duray, P. H.; Gonzalez, S.; Velasco, A.; Linehan, W. M.; Matusik, R. J.; Price, D. K.; Figg, W. D.; Emmert-Buck, M. R.; Chuaqui, R. F.
  3. Clinical Cancer Research. 2005, OCT 1; 11(19, Part 1): 6823-6834.
  1. 14.   Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation
  2. Hodge, D. R.; Peng, B.; Cherry, J. C.; Hurt, E. M.; Fox, S. D.; Kelley, J. A.; Munroe, D. J.; Farrar, W. L.
  3. Cancer Research. 2005, JUN 1; 65(11): 4673-4682.
  1. 15.   Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6/1 cells
  2. Pengt, B.; Hodge, D. R.; Thomas, S. B.; Cherry, J. M.; Munroe, D. J.; Pompeia, C.; Xiao, W. H.; Farrar, W. L.
  3. Journal of Biological Chemistry. 2005, FEB 11; 280(6): 4182-4187.
  1. 16.   Nuclear receptors as negative modulators of STAT3 in multiple myeloma
  2. Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Farrar, W. L.
  3. Cell Cycle. 2005, FEB; 4(2): 242-245.
  1. 17.   Endogenous leukemia inhibitory factor attenuates endotoxin response
  2. Weber, M. A.; Schnyder-Candrian, S.; Schnyder, B.; Quesniaux, V.; Poli, V.; Stewart, C. L.; Ryffel, B.
  3. Laboratory Investigation. 2005, FEB; 85(2): 276-284.
  1. 18.   The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappa B activity in drug-sensitive MCF-7 cells
  2. Brantley, E.; Patel, V.; Stinson, S. F.; Trapani, V.; Hose, C. D.; Ciolino, H. P.; Yeh, G. C.; Gutkind, J. S.; Sausville, E. A.; Loaiza-Perez, A. I.
  3. Anti-Cancer Drugs. 2005, FEB; 16(2): 137-143.
  1. 19.   Triptolide attenuates endotoxin- and staphylococcal exotoxin-induced T-cell proliferation and production of cytokines and chemokines
  2. Krakauer, T.; Chen, X.; Howard, O. M. Z.; Young, H. A.
  3. Immunopharmacology and Immunotoxicology. 2005 27(1): 53-66.
  1. 20.   Co-operative functions between nuclear factors NF kappa B and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells
  2. Xiao, W. H.; Hodge, D. R.; Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Farrar, W. L.
  3. Prostate. 2004, DEC 1; 61(4): 354-370.
  1. 21.   Mammary gland remodeling depends on gp130 signaling through Stat3 and MAPK
  2. Zhao, L.; Hart, S.; Cheng, J. G.; Melenhorst, J. J.; Bierie, B.; Ernst, M.; Stewart, C.; Schaper, F.; Heinrich, P. C.; Ullrich, A.; Robinson, G. W.; Hennighausen, L.
  3. Journal of Biological Chemistry. 2004, OCT 15; 279(42): 44093-44100.
  1. 22.   Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells
  2. Hodge, D. R.; Xiao, W. H.; Wang, L. H.; Li, D. P.; Farrar, W. L.
  3. Cancer Biology & Therapy. 2004 3(2): 188-194.
  1. 23.   Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line
  2. Pompeia, C.; Hodge, D. R.; Plass, C.; Wu, Y. Z.; Marquez, V. E.; Kelley, J. A.; Farrar, W. L.
  3. Cancer Research. 2004 64(10): 3465-3473.
  1. 24.   Transcriptional inactivation of STAT3 by PPAR gamma suppresses IL-6-responsive multiple myeloma cells
  2. Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Huang, J. Q.; Hou, J.; Li, J.; Xiong, H.; Mihalic, K.; Zhu, H. M.; Xiao, W. H.; Farrar, W. L.
  3. Immunity. 2004 20(2): 205-218.
  1. 25.   Interleukin-6 haplotypes, inflammation, and risk of cardiovascular disease in a MultiEthnic dialysis cohort
  2. Liu, Y. M.; Berthier-Schaad, Y.; Fallin, D. M.; Fink, N.; Tracy, R. P.; Klag, M. J.; Smith, M. W.; Coresh, J.
  3. Circulation. 2003 108(17): 3460.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel